TPC invests in MIGENIX’s new antibiotic drug

Guest Contributor
April 12, 2005

MIGENIX Inc of Vancouver has received $9.3 million from Technology Partnerships Canada to launch a $35.6-million R&D project to further develop its MX-2401 antibiotic drug. The project is intended to increase the drug’s efficacy against skin and soft tissue infections as well as the development of a cost-effective manufacturing process. Pre-clinical testing of MX-2401 — a lipopeptide-based compound derived from amphomycin — could demonstrate a low likelihood of rapid development of resistance and cross-resistance to many infections acquired in hospital....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.